Theresa
Greupner
a,
Laura
Kutzner
b,
Svenja
Pagenkopf
a,
Heike
Kohrs
a,
Andreas
Hahn
a,
Nils Helge
Schebb
bc and
Jan Philipp
Schuchardt
*a
aInstitute of Food Science and Human Nutrition, Leibniz University Hannover, Germany. E-mail: schuchardt@nutrition.uni-hannover.de; Fax: +49 (0)511-7625729; Tel: +49 (0)511-762 2987
bInstitute for Food Toxicology, University of Veterinary Medicine Hannover, Germany
cChair of Food Chemistry, Faculty of Mathematics and Natural Sciences, University of Wuppertal, Germany
First published on 13th August 2018
There is a debate about the optimal dietary ratio of the parent n6 fatty acid linoleic acid (LA) and n3 fatty acid alpha-linolenic acid (ALA) to promote an efficient conversion of ALA to EPA and DHA, which have implications for human health. The aim of the present study was to compare the effects of a low-LA/high-ALA (loLA/hiALA) diet with a high-LA/low-ALA (hiLA/loALA) diet on fatty acid concentrations in red blood cells (RBCs). Fifteen omnivore healthy men (mean age 26.1 ± 4.5 years) with a low initial EPA/DHA status (sum (∑) EPA + DHA% of total fatty acids in RBC at baseline: 4.03 ± 0.17) received both diets for two weeks with a nine-week wash-out phase in between. Fatty acid intake of the subjects was tightly controlled. Concentrations [μg mL−1] and relative amounts [% of total fatty acids] of fatty acids in RBCs were analyzed at baseline (day 0), day 7 and 14 by means of GC-FID. The dietary LA/ALA ratios were 0.56 ± 0.27:1 and 25.6 ± 2.41:1 and led to significantly different changes of ALA, LA, EPA and ∑EPA + DHA concentrations in RBCs. In the course of the loLA/hiALA diet ALA and EPA concentrations and relative amounts of ∑EPA + DHA increased, whereas LA concentrations decreased. The DHA concentration was unaffected. The hiLA/loALA diet led to slightly decreased EPA concentrations, while all other fatty acid concentrations remained constant. Compared to our previous study, where we simply increased the ALA intake, our results show that ALA supplementation combined with a reduced LA intake (loLA/hiALA diet) more efficiently enhanced EPA blood concentrations. The absence of changes in the PUFA pattern in consequence of a LA/ALA ratio of 25.6 ± 2.41:1 suggests that the high LA/ALA ratio of the Western diet already leads to a saturation and a further increase of the ratio does not affect the PUFA pattern.
The essential n3 precursor fatty acid alpha-linolenic acid (ALA, C18:3n3) is present in high amounts in some plant oils, particularly linseed-, chia-, perilla- and walnut oil and can be converted into EPA and DHA in a multistep elongation and desaturation reaction.10 However, the efficiency of this process is generally low in adult humans.11 It is, inter alia, influenced by the intake of the n6 precursor fatty acid linoleic acid (LA, C18:2n6) due to competition for the same desaturation and elongation enzymes12,13 and for incorporation into cell membranes.14 The intake of LA has increased substantially in Western diets during the last century.15,16 Consequently, the dietary ratio of the n6 fatty acid LA to the n3 fatty acid ALA is about 10–20:1 (ref. 17–19) which is viewed as unfavorable and may result in an inefficient conversion of ALA to the physiologically important n3 PUFAs EPA and DHA.12,13 A reduction of LA has been suggested to enhance the conversion of ALA to the longer chain n3 PUFAs EPA and DHA. Therefore, the biological efficacy of n3 PUFAs is improved and at the same time production of n6 derived pro-inflammatory mediators is decreased.20
The aim of our study was to compare two extreme ratios of LA to ALA involving a low-LA/high-ALA (loLA/hiALA) diet with a ratio of 0.5–1:1 and a high-LA/low-ALA (hiLA/loALA) diet with a ratio of LA 20–30:1 on fatty acid concentrations in red blood cells (RBCs) with special emphasis on EPA and DHA. To achieve the two dietary LA/ALA ratios, the fatty acid supply of the subjects was tightly controlled via a multistep method. A homogenous collective of healthy men in a narrow age class was chosen to minimize potential fluctuations due to age21,22 and hormonal influences.23
The study was conducted at the Institute of Food Science and Human Nutrition, Leibniz University Hannover, Germany. It consisted of a screening phase, two four-week run-in phases, a nine-week wash-out phase and two 14-day intervention phases (Fig. 1). In each intervention phase three examinations were carried out: at baseline (day 0), after 7 (day 7) and after 14 days (day 14). In the run-in phases the participants were requested to abstain from fish, seafood, and ALA-rich vegetable oils such as linseed oil or chia seeds. The aim of the intervention periods was to obtain two different dietary ratios of LA to ALA (0.5–1:1 and 20–30:1). Due to the cross-over design, each subject acted as its own control, which minimizes interindividual variability of blood fatty acid levels as well as potential fluctuations regarding dietary intakes between individuals.
Fig. 1 Schematic presentation of the study methods. ALA: α-linolenic acid; LA: linoleic acid; PUFA: polyunsaturated fatty acids. |
The control of the fatty acid intake was achieved by the following measures:
(A) Daily provision of the lunch meal by the Institute of Food Science and Human Nutrition, Leibniz University Hannover. The aim was to provide the same quantities of PUFAs to the participants. The daily freshly cooked lunch was low in LA and practically free of n3 fatty acids including ALA, EPA and DHA. The lunch meals were identical in both intervention phases. Subjects were allowed to eat lunch meals ad libitum. The consumed portions were all weighed.
(B) Complete replacement and standardization of the spreadable fat. Participants had to consume 60 g of provided margarine per week in both intervention phases, which should replace other spreadable fat. The margarine had a fat content of 74.3 g per 100 g with a LA content of 15.2% and an ALA content of 6.8%. Via margarine, participants therefore consumed 0.97 g LA and 0.43 g ALA per day.
(C) Daily supplementation of an ALA- and a LA-rich vegetable oil to adjust the intake of LA and ALA of the participants. In the intervention period with the loLA/hiALA diet subjects daily ingested 22.3 g of linseed oil with an ALA content of 55.9% of total fatty acids (Table 1) resulting in a daily ALA intake from linseed oil of 12.5 g per day. In the intervention period with the hiLA/loALA diet, subjects ingested a daily dose of 22.3 g of sunflower oil with a LA content of 62.5% (Table 1). Hence, daily LA intake from sunflower oil was 13.9 g per day.
Fatty acid | Common name | Margarine | Linseed oil | Sunflower oil |
---|---|---|---|---|
C12:0 | Lauric acid | 6.2 | — | — |
C14:0 | Myristic acid | 2.5 | — | — |
C16:0 | Palmitic acid | 22.1 | 6.0 | 6.1 |
C18:0 | Stearic acid | 2.4 | 4.9 | 3.2 |
C18:1n9 | Oleic acid | 44.8 | 19.3 | 28.2 |
C18:2n6 | Linoleic acid | 15.2 | 13.9 | 62.5 |
C18:3n3 | α-Linolenic acid | 6.8 | 55.9 | — |
C20:0 | Arachidic acid | — | — | — |
C22:0 | Behenic acid | — | — | — |
C24:0 | Lignoceric acid | — | — | — |
(D) Subjects were instructed to consume a low-fat and PUFA-poor diet containing no vegetable fats, but lots of fruit and vegetables, low-fat dairy products and white flour products. The subjects were provided with take-away foods (e.g. fruits, vegetable-soups, white bread) to help them comply with the PUFA-poor diet. The participants were requested to maintain their diet unchanged during both intervention phases.
The subjects had to record the consumed foods and drinks during both intervention phases in (daily) nutritional records. The nutritional records were checked daily for the requested nutrition, completeness, readability and plausibility by nutritionists and, if necessary, ambiguities were clarified directly with the subjects. The analysis of energy and nutrient intake was implemented using PRODI® (Nutri-Science GmbH, Freiburg, Germany). In addition, the fat content and the fatty acid composition of the provided lunch was analyzed by GC and included in the PRODI® analysis.
The distributions of the sample sets were analyzed by means of the Kolmogorov–Smirnov test. t-Tests for paired samples were used to determine statistical significance between the two interventions at baseline (day 0), after seven days (day 7) and after 14 days (day 14). To examine differences between the two interventions, two-factorial ANOVAs with repeated measurements of both factors were used. One-factorial ANOVAs with repeated measurements were carried out to examine the effect of time within the two interventions (day 0, day 7, day 14) separately for each intervention. Post-hoc t-tests for paired samples with Holm–Bonferroni-adjusted levels of significance were used to evaluate differences between the time points. Statistical significance was set at p ≤ 0.05 for all analyses. All statistical analyses were carried out with SPSS software (Version 24, SPSS Inc., Chicago, IL, USA).
During the intervention periods, mean fruit and vegetable consumption increased to 5 portions per day, meat intake decreased to 2 portions per week and fish was not consumed during the intervention periods.
The examination of the dietary records combined with analysis of fatty acids in the lunch meal showed that the LA intake was 7.30 ± 0.37 g d−1 (2.78 en%) during loLA/hiALA diet and 18.2 ± 0.54 g d−1 (6.95 en%) during hiLA/loALA diet, while the ALA intake was 13.1 ± 0.22 g d−1 (4.98 en%) during loLA/hiALA diet and 0.71 ± 0.09 g d−1 (0.27 en%) during hiLA/loALA diet. The actual dietary LA/ALA ratios were therefore 0.56 ± 0.27:1 in the loLA/hiALA diet and 25.6 ± 2.41:1 in the hiLA/loALA diet (Table 2). Intake of arachidonic acid (AA), EPA, DPAn3 and DHA was very low and did not differ between both intervention periods. Total PUFA intake was significantly higher during loLA/hiALA diet (22.5 ± 0.64 g d−1) compared to hiLA/loALA diet (18.5 ± 1.11 g d−1), while saturated fatty acid (SFA) and monounsaturated fatty acid (MUFA) intake were marginally, but significantly, higher during hiLA/loALA diet. However, fat intake as well as energy, protein, and carbohydrate intake did not differ between both intervention periods (Table 2).
loLA /hiALA | hiLA/loALA | t-Testa | |
---|---|---|---|
Mean ± SD | Mean ± SD | ||
AA: arachidonic acid; ALA: α-linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; DPAn3: n3 docosapentaenoic acid; LA: linoleic acid; MUFA: monounsaturated fatty acids; n.s.: not significant; PUFA: polyunsaturated fatty acids; SFA: saturated fatty acids.a t-Test for paired samples; significance level p ≤ 0.05b Energy, protein, total fat, SFA, MUFA and PUFA intake were calculated from analyses of dietary records with PRODI®c LA, ALA, AA, EPA, DPAn3 and DHA intake were calculated from a combination of own analyses of meals that were provided by the Institute of Food Science and Human Nutrition and analyses of dietary records with PRODI®. | |||
Energy intakeb (kcal) | 2444 ± 327 | 2436 ± 340 | n.s. |
Proteinb (g) | 95.5 ± 16.1 | 95.9 ± 16.4 | n.s. |
Carbohydratesb (g) | 325 ± 54.2 | 322 ± 54.2 | n.s. |
Total fat intakeb (g) | 67.6 ± 5.43 | 68.5 ± 6.93 | n.s. |
SFAb (g) | 17.3 ± 2.23 | 19.4 ± 2.26 | 0.040 |
MUFAb (g) | 10.2 ± 0.93 | 11.8 ± 1.41 | <0.001 |
PUFAb (g) | 22.5 ± 0.64 | 18.5 ± 1.11 | <0.001 |
LAc (g) | 7.30 ± 0.37 | 18.2 ± 0.54 | <0.001 |
ALAc (g) | 13.1 ± 0.22 | 0.71 ± 0.09 | <0.001 |
LA/ALAc | 0.56 ± 0.27:1 | 25.6 ± 2.41:1 | — |
AAc (g) | 0.02 ± 0.01 | 0.02 ± 0.01 | n.s. |
EPAc (g) | 0.00 ± 0.00 | 0.00 ± 0.00 | n.s. |
DPAn3c (g) | 0.01 ± 0.01 | 0.01 ± 0.01 | n.s. |
DHAc (g) | 0.03 ± 0.01 | 0.02 ± 0.01 | n.s. |
Clinical and anthropometric parameters of the participants were not significantly different between both interventions at baseline (Table 3). A slight decrease in body weight, BMI, total cholesterol (TC), low density lipoprotein (LDL) and high density lipoprotein (HDL) was observed in both intervention periods. During hiLA/loALA diet, but not during loLA/hiALA diet, the diastolic blood pressure decreased. All other parameters remained constant in both intervention periods (Table 3).
loLA/hiALA | An reM | hiLA/loALA | An reM | |||||
---|---|---|---|---|---|---|---|---|
Day 0 | Day 7 | Day 14 | Day 0 | Day 7 | Day 14 | |||
Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |||
Levels are shown at day 0, 7 and 14 of loLA/hiALA diet and hiLA/loALA diet. An reM: ANOVA for repeated measures; BMI: body mass index; dias BP: diastolic blood pressure; HDL: high density lipoprotein; LDL: low density lipoprotein; SD: standard deviation; sys BP: systolic blood pressure; TC: total cholesterol; TG: triglycerides. aSignificant difference between loLA/hiALA diet week 0 and hiLA/loALA diet week 0 (t-test for paired samples). bSignificant difference between loLA/hiALA diet week 1 and hiLA/loALA diet week 1 (t-test for paired samples). cSignificant difference between loLA/hiALA diet week 2 and hiLA/loALA diet week 2 (t-test for paired samples). dSignificant difference between week 0 and week 2 of loLA/hiALA diet /hiLA/loALA diet (t-test for paired samples). eSignificant difference within loLA/hiALA diet (one-factorial ANOVA for repeated measures). fSignificant difference within hiLA/loALA diet (one-factorial ANOVA for repeated measures). gSignificant difference within loLA/hiALA diet between week 0 and week 1 (t-test for paired samples with Holm–Bonferroni correction). hSignificant difference within loLA/hiALA diet between week 0 and week 2 (t-test for paired samples with Holm–Bonferroni correction). iSignificant difference within hiLA/loALA between week 0 and week 1 (t-test for paired samples with Holm–Bonferroni correction). kSignificant difference within hiLA/loALA between week 0 and week 2 (t-test for paired samples with Holm–Bonferroni correction). lSignificant difference between loLA/hiALA diet und hiLA/loALA (two-factorial ANOVA for repeated measures). *p ≤ 0.05, #p ≤ 0.005, ‡p < 0.001. | ||||||||
Age (years) | 26.1 ± 4.53 | |||||||
Weight (kg) | 81.4 ± 7.44 | 80.1 ± 7.49d‡ | 81.9 ± 8.11 | 80.9 ± 8.09d‡ | ||||
BMI (kg m−2) | 24.0 ± 1.65 | 23.6 ± 1.70d‡ | 24.2 ± 1.81 | 23.9 ± 1.82d‡ | ||||
Sys BP (mmHg) | 127 ± 7.99 | 124 ± 10.7 | 125 ± 12.0 | 129 ± 11.0 | 124 ± 11.8 | 126 ± 13.2 | ||
Dias BP (mmHg) | 77.7 ± 4.58 | 77.7 ± 5.30b* | 76.0 ± 6.32 | 78.0 ± 6.21 | 73.7 ± 6.11b* | 74.0 ± 5.73k* | f* | |
TC (mg dl−1) | 177 ± 42.8 | 155 ± 32.4g# | 150 ± 27.0h# | e‡ | 169 ± 34.8 | 148 ± 30.7i‡ | 152 ± 37.9k* | f# |
HDL (mg dl−1) | 56.5 ± 9.64 | 51.5 ± 9.53g* | 49.7 ± 8.78h* | e‡ | 58.9 ± 9.77 | 51.5 ± 7.83i‡ | 53.0 ± 9.82 | f# |
LDL (mg dl−1) | 110 ± 31.4 | 97.9 ± 26.4b*, g* | 93.7 ± 18.9h* | e# | 106 ± 28.5 | 91.0 ± 24.5b*, i‡ | 91.8 ± 27.5k# | f‡ |
TG (mg dl−1) | 106 ± 50.8 | 100 ± 44.6 | 107 ± 46.7 | 108 ± 36.0 | 98.5 ± 31.3 | 99.9 ± 54.8 |
Day 0 | Day 7 | t-Testa | Day 14 | t-Testa | 1-fact. An reMb | |
---|---|---|---|---|---|---|
Mean ± SE | Mean ± SE | p (day 7–day 0) | Mean ± SE | p (day 14–day 0) | p | |
Levels are shown as concentration [μg mL−1] in blood and as relative amount [%] of total fatty acids. An reM: ANOVA for repeated measures; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; MUFA: monounsaturated fatty acids: C14:1n5, C15:1n5, C16:1n7, C17:1n7, C18:1n9, C18:1n7, C20:1n9, C22:1n9, 24:1n9; n.s.: not significant; SFA: saturated fatty acids: C10:0, C11:0, C12:0, C13:0, C14:0, C15:0, C16:0, C17:0, C18:0, C20:0, C21:0, C22:0, C24:0; PUFA: polyunsaturated fatty acids: C18:2n6, C18:3n6, C18:3n3, C:18:4n3, C20:2n6, C20:3n3, C20:3n6, C20:3n9, C20:4n3, C20:4n6, C20:5n3, C22:2n6, C22:4n6, C22:5n3, C22:5n6, C22:6n3; TFA: total fatty acids.a t-Test for paired samples with Holm–Bonferroni correction (within intervention); significance level p ≤ 0.05b One-factorial ANOVA for repeated measures (An reM); significance level p ≤ 0.05. | ||||||
C10:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C11:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C12:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C13:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C14:0 (μg mL−1) | 3.31 ± 0.16 | 3.15 ± 0.17 | — | 2.78 ± 0.21 | — | n.s. |
% of total FA | 0.32 ± 0.02 | 0.31 ± 0.01 | — | 0.30 ± 0.02 | — | n.s. |
C14:1n5 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C15:0 (μg mL−1) | 1.59 ± 0.08 | 1.61 ± 0.06 | — | 1.37 ± 0.07 | — | n.s. |
% of total FA | 0.15 ± 0.01 | 0.16 ± 0.00 | — | 0.15 ± 0.01 | — | n.s. |
C15:1n5 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C16:0 (μg mL−1) | 212 ± 7.22 | 209 ± 5.89 | n.s. | 184 ± 6.24 | n.s. | 0.017 |
% of total FA | 20.4 ± 0.18 | 20.7 ± 0.13 | n.s. | 19.8 ± 0.18 | n.s. | 0.005 |
C16:1n7 (μg mL−1) | 2.88 ± 0.18 | 3.11 ± 0.32 | — | 2.89 ± 0.37 | — | n.s. |
% of total FA | 0.28 ± 0.02 | 0.30 ± 0.02 | — | 0.31 ± 0.03 | — | n.s. |
C17:0 (μg mL−1) | 3.10 ± 0.12 | 3.07 ± 0.08 | <0.001 | 2.76 ± 0.08 | n.s. | <0.001 |
% of total FA | 0.30 ± 0.01 | 0.31 ± 0.01 | <0.001 | 0.30 ± 0.01 | n.s. | <0.001 |
C17:1n8 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C18:0 (μg mL−1) | 157 ± 4.53 | 154 ± 3.82 | — | 141 ± 3.85 | — | n.s. |
% of total FA | 15.2 ± 0.18 | 15.3 ± 0.13 | — | 15.2 ± 0.15 | — | n.s. |
C18:1n9 (μg mL−1) | 139 ± 4.78 | 130 ± 4.69 | n.s. | 117 ± 5.25 | n.s. | 0.016 |
% of total FA | 13.4 ± 0.18 | 12.8 ± 0.21 | 0.001 | 12.6 ± 0.25 | <0.001 | <0.001 |
C18:1n7 (μg mL−1) | 14.5 ± 0.59 | 14.3 ± 0.42 | — | 13.5 ± 0.33 | — | n.s. |
% of total FA | 1.40 ± 0.02 | 1.42 ± 0.02 | n.s. | 1.45 ± 0.02 | n.s. | 0.019 |
C18:2n6 (μg mL−1) | 101 ± 3.78 | 91.6 ± 2.59 | n.s. | 82.8 ± 2.75 | n.s. | 0.029 |
% of total FA | 9.72 ± 0.20 | 9.12 ± 0.19 | n.s. | 8.90 ± 0.15 | n.s. | 0.012 |
C18:3n6 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C19:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C18:3n3 (μg mL−1) | 1.44 ± 0.17 | 5.63 ± 0.45 | <0.001 | 6.34 ± 0.63 | <0.001 | <0.001 |
% of total FA | 0.14 ± 0.02 | 0.55 ± 0.03 | <0.001 | 0.67 ± 0.05 | <0.001 | <0.001 |
C18:4n3 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C20:0 (μg mL−1) | 3.87 ± 0.14 | 3.92 ± 0.12 | — | 3.71 ± 0.14 | — | n.s. |
% of total FA | 0.37 ± 0.01 | 0.39 ± 0.01 | — | 0.40 ± 0.01 | — | n.s. |
C20:1n9 (μg mL−1) | 2.86 ± 0.21 | 2.79 ± 0.13 | — | 2.52 ± 0.10 | — | n.s. |
% of total FA | 0.27 ± 0.01 | 0.28 ± 0.01 | — | 0.27 ± 0.01 | — | n.s. |
C20:2n6 (μg mL−1) | 2.00 ± 0.12 | 1.87 ± 0.10 | — | 1.62 ± 0.07 | — | n.s. |
% of total FA | 0.19 ± 0.01 | 0.19 ± 0.01 | — | 0.18 ± 0.01 | — | n.s. |
C20:3n9 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C20:3n6 (μg mL−1) | 15.9 ± 0.93 | 14.1 ± 0.96 | — | 12.9 ± 0.94 | — | n.s. |
% of total FA | 1.53 ± 0.07 | 1.39 ± 0.08 | — | 1.38 ± 0.10 | — | n.s. |
C21:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C20:4n6 (μg mL−1) | 152 ± 4.08 | 147 ± 3.61 | — | 139 ± 3.16 | — | n.s. |
% of total FA | 14.7 ± 0.18 | 14.7 ± 0.20 | — | 15.0 ± 0.27 | — | n.s. |
C20:3n3 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C20:4n3 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C20:5n3 (μg mL−1) | 5.49 ± 0.48 | 6.97 ± 0.55 | 0.019 | 8.27 ± 0.82 | 0.008 | 0.002 |
% of total FA | 0.53 ± 0.04 | 0.69 ± 0.05 | 0.009 | 0.88 ± 0.08 | <0.001 | <0.001 |
C22:0 (μg mL−1) | 16.6 ± 0.36 | 16.5 ± 0.54 | — | 15.5 ± 0.49 | — | n.s. |
% of total FA | 1.61 ± 0.04 | 1.64 ± 0.03 | — | 1.66 ± 0.04 | — | n.s. |
C22:1n9 (μg mL−1) | 1.56 ± 0.20 | 2.08 ± 0.28 | — | 1.94 ± 0.34 | — | n.s. |
% of total FA | 0.15 ± 0.02 | 0.20 ± 0.03 | — | 0.21 ± 0.04 | — | n.s. |
C22:2n6 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C22:4n6 (μg mL−1) | 32.5 ± 1.58 | 30.7 ± 1.21 | — | 27.9 ± 1.11 | — | n.s. |
% of total FA | 3.13 ± 0.11 | 3.06 ± 0.11 | — | 3.01 ± 0.11 | — | n.s. |
C22:5n6 (μg mL−1) | 5.84 ± 0.35 | 5.49 ± 0.34 | — | 5.11 ± 0.32 | — | n.s. |
% of total FA | 0.56 ± 0.03 | 0.54 ± 0.03 | — | 0.55 ± 0.03 | — | n.s. |
C22:5n3 (μg mL−1) | 27.3 ± 1.42 | 27.1 ± 1.05 | — | 27.1 ± 1.34 | — | n.s. |
% of total FA | 2.62 ± 0.09 | 2.70 ± 0.09 | n.s. | 2.91 ± 0.10 | 0.004 | 0.002 |
C24:0 (μg mL−1) | 47.1 ± 1.14 | 45.9 ± 1.21 | — | 44.1 ± 1.29 | — | n.s. |
% of total FA | 4.56 ± 0.06 | 4.56 ± 0.05 | n.s. | 4.75 ± 0.06 | n.s. | 0.031 |
C22:6n3 (μg mL−1) | 36.1 ± 1.75 | 35.8 ± 1.75 | — | 35.8 ± 1.44 | — | n.s. |
% of total FA | 3.50 ± 0.15 | 3.56 ± 0.16 | — | 3.87 ± 0.16 | — | n.s. |
C24:1n9 (μg mL−1) | 51.9 ± 2.42 | 50.7 ± 1.73 | — | 49.1 ± 1.34 | — | n.s. |
% of total FA | 4.99 ± 0.13 | 5.04 ± 0.11 | — | 5.30 ± 0.14 | — | n.s. |
∑TFA (μg mL−1) | 1040 ± 30.9 | 1010 ± 25.9 | — | 933 ± 25.8 | — | n.s. |
∑SFA (μg mL−1) | 446 ± 13.1 | 438 ± 11.1 | n.s. | 396 ± 11.5 | n.s. | 0.031 |
% of total FA | 42.9 ± 0.30 | 43.4 ± 0.13 | n.s. | 42.5 ± 0.18 | n.s. | 0.025 |
∑MUFA (μg mL−1) | 213 ± 7.87 | 203 ± 6.87 | n.s. | 188 ± 6.85 | n.s. | 0.039 |
% of total FA | 20.5 ± 0.31 | 20.1 ± 0.27 | n.s. | 20.1 ± 0.32 | n.s. | 0.036 |
∑PUFA (μg mL−1) | 381 ± 11.0 | 369 ± 8.72 | — | 349 ± 8.62 | — | n.s. |
% of total FA | 36.7 ± 0.19 | 36.5 ± 0.20 | n.s. | 37.5 ± 0.28 | n.s. | 0.002 |
∑EPA + DHA (μg mL−1) | 41.6 ± 2.04 | 42.8 ± 2.04 | — | 44.1 ± 1.96 | — | n.s. |
% of total FA | 4.03 ± 0.17 | 4.25 ± 0.18 | n.s. | 4.76 ± 0.20 | 0.019 | 0.001 |
Day 0 | Day 7 | t-Testa | Day 14 | t-Testa | 1-fact. An reMb | |
---|---|---|---|---|---|---|
Mean ± SE | Mean ± SE | p (day 7–day 0) | Mean ± SE | p (day 14–day 0) | p | |
Levels are shown as concentration [μg mL−1] in blood and as relative amount [%] of total fatty acids. An reM: ANOVA for repeated measures; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; MUFA: monounsaturated fatty acids: C14:1n5, C15:1n5, C16:1n7, C17:1n7, C18:1n9, C18:1n7, C20:1n9, C22:1n9, 24:1n9; n.s.: not significant; SFA: saturated fatty acids: C10:0, C11:0, C12:0, C13:0, C14:0, C15:0, C16:0, C17:0, C18:0, C20:0, C21:0, C22:0, C24:0; PUFA: polyunsaturated fatty acids: C18:2n6, C18:3n6, C18:3n3, C:18:4n3, C20:2n6, C20:3n3, C20:3n6, C20:3n9, C20:4n3, C20:4n6, C20:5n3, C22:2n6, C22:4n6, C22:5n3, C22:5n6, C22:6n3; TFA: total fatty acids.a t-Test for paired samples with Holm–Bonferroni correction (within intervention); significance level p ≤ 0.05b One-factorial ANOVA for repeated measures (An reM); significance level p ≤ 0.05. | ||||||
C10:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C11:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C12:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C13:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C14:0 (μg mL−1) | 3.07 ± 0.17 | 3.06 ± 0.12 | n.s. | 3.53 ± 0.21 | 0.029 | 0.006 |
% of total FA | 0.31 ± 0.01 | 0.32 ± 0.01 | — | 0.34 ± 0.01 | — | n.s. |
C14:1n5 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C15:0 (μg mL−1) | 1.51 ± 0.05 | 1.51 ± 0.05 | n.s. | 1.70 ± 0.07 | 0.045 | 0.008 |
% of total FA | 0.15 ± 0.00 | 0.16 ± 0.00 | n.s. | 0.16 ± 0.01 | n.s. | 0.041 |
C15:1n5 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C16:0 (μg mL−1) | 200 ± 4.48 | 194 ± 4.23 | n.s. | 218 ± 6.47 | 0.043 | 0.001 |
% of total FA | 20.1 ± 0.13 | 20.5 ± 0.11 | <0.001 | 21.0 ± 0.13 | <0.001 | <0.001 |
C16:1n7 (μg mL−1) | 2.87 ± 0.13 | 2.98 ± 0.16 | n.s. | 3.67 ± 0.47 | n.s. | 0.041 |
% of total FA | 0.29 ± 0.01 | 0.32 ± 0.02 | — | 0.35 ± 0.04 | — | n.s. |
C17:0 (μg mL−1) | 2.96 ± 0.09 | 2.87 ± 0.06 | <0.001 | 3.10 ± 0.08 | n.s. | <0.001 |
% of total FA | 0.30 ± 0.01 | 0.30 ± 0.01 | <0.001 | 0.30 ± 0.01 | n.s. | <0.001 |
C17:1n8 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C18:0 (μg mL−1) | 151 ± 3.50 | 142 ± 3.20 | 0.018 | 154 ± 4.25 | n.s. | 0.017 |
% of total FA | 15.3 ± 0.10 | 15.1 ± 0.12 | n.s. | 14.8 ± 0.15 | 0.029 | 0.009 |
C18:1n9 (μg mL−1) | 130 ± 2.65 | 121 ± 2.56 | 0.005 | 133 ± 5.29 | n.s. | 0.011 |
% of total FA | 13.1 ± 0.20 | 12.8 ± 0.18 | 0.011 | 12.7 ± 0.25 | n.s. | 0.036 |
C18:1n7 (μg mL−1) | 13.8 ± 0.34 | 13.5 ± 0.30 | n.s. | 15.2 ± 0.53 | n.s. | 0.008 |
% of total FA | 1.39 ± 0.02 | 1.44 ± 0.02 | n.s. | 1.46 ± 0.03 | n.s. | 0.022 |
C18:2n6 (μg mL−1) | 99.1 ± 2.89 | 94.5 ± 2.92 | n.s. | 110 ± 3.51 | n.s. | 0.001 |
% of total FA | 9.99 ± 0.24 | 10.0 ± 0.23 | n.s. | 10.6 ± 0.22 | n.s. | 0.011 |
C18:3n6 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C19:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C18:3n3 (μg mL−1) | 1.47 ± 0.13 | 1.09 ± 0.09 | 0.011 | 1.41 ± 0.17 | n.s. | 0.008 |
% of total FA | 0.15 ± 0.01 | 0.12 ± 0.01 | 0.023 | 0.13 ± 0.01 | n.s. | 0.016 |
C18:4n3 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C20:0 (μg mL−1) | 4.06 ± 0.11 | 3.70 ± 0.13 | — | 3.95 ± 0.15 | — | n.s. |
% of total FA | 0.41 ± 0.01 | 0.39 ± 0.01 | — | 0.38 ± 0.01 | — | n.s. |
C20:1n9 (μg mL−1) | 2.73 ± 0.13 | 2.57 ± 0.13 | 0.038 | 2.87 ± 0.12 | n.s. | 0.010 |
% of total FA | 0.28 ± 0.01 | 0.27 ± 0.01 | — | 0.28 ± 0.01 | — | n.s. |
C20:2n6 (μg mL−1) | 1.89 ± 0.08 | 1.85 ± 0.09 | — | 2.21 ± 0.11 | — | n.s. |
% of total FA | 0.19 ± 0.01 | 0.20 ± 0.01 | — | 0.21 ± 0.01 | — | n.s. |
C20:3n9 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C20:3n6 (μg mL−1) | 14.5 ± 0.82 | 14.1 ± 0.82 | n.s. | 15.9 ± 0.89 | n.s. | 0.010 |
% of total FA | 1.47 ± 0.08 | 1.50 ± — | n.s. | 1.54 ± 0.09 | — | n.s. |
C21:0 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C20:4n6 (μg mL−1) | 145 ± 4.10 | 138 ± 3.33 | n.s. | 151 ± 3.86 | n.s. | 0.011 |
% of total FA | 14.6 ± 0.19 | 14.7 ± 0.14 | — | 14.6 ± 0.20 | — | n.s. |
C20:3n3 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C20:4n3 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C20:5n3 (μg mL−1) | 5.86 ± 0.41 | 5.21 ± 0.35 | 0.002 | 5.11 ± 0.41 | 0.025 | 0.001 |
% of total FA | 0.59 ± 0.04 | 0.55 ± 0.04 | 0.001 | 0.49 ± 0.03 | <0.001 | <0.001 |
C22:0 (μg mL−1) | 16.5 ± 0.55 | 15.28 ± 0.54 | 0.025 | 16.6 ± 0.51 | n.s. | 0.017 |
% of total FA | 1.66 ± 0.04 | 1.62 ± 0.03 | — | 1.60 ± 0.04 | — | n.s. |
C22:1n9 (μg mL−1) | 2.03 ± 0.20 | 1.83 ± 0.21 | n.s. | 1.30 ± 0.12 | n.s. | 0.033 |
% of total FA | 0.21 ± 0.02 | 0.19 ± 0.02 | n.s. | 0.13 ± 0.01 | n.s. | 0.023 |
C22:2n6 (μg mL−1) | <0.25 | <0.25 | — | <0.25 | — | — |
% of total FA | — | — | — | — | — | — |
C22:4n6 (μg mL−1) | 29.5 ± 0.92 | 28.58 ± 1.25 | n.s. | 30.4 ± 1.13 | n.s. | 0.014 |
% of total FA | 2.98 ± 0.11 | 3.03 ± 0.11 | — | 2.93 ± 0.09 | — | n.s. |
C22:5n6 (μg mL−1) | 5.12 ± 0.24 | 5.04 ± 0.29 | n.s. | 5.42 ± 0.25 | n.s. | 0.015 |
% of total FA | 0.52 ± 0.02 | 0.53 ± 0.03 | — | 0.52 ± 0.02 | — | n.s. |
C22:5n3 (μg mL−1) | 28.0 ± 0.98 | 27.03 ± 0.91 | — | 27.9 ± 1.51 | — | n.s. |
% of total FA | 2.82 ± 0.09 | 2.87 ± 0.08 | n.s. | 2.67 ± 0.10 | 0.021 | 0.001 |
C24:0 (μg mL−1) | 46.7 ± 1.11 | 44.00 ± 1.36 | 0.032 | 46.6 ± 1.48 | n.s. | n.s. |
% of total FA | 4.70 ± 0.06 | 4.65 ± 0.07 | n.s. | 4.48 ± 0.08 | 0.020 | 0.001 |
C22:6n3 (μg mL−1) | 34.3 ± 2.04 | 32.4 ± 1.75 | n.s. | 35.68 ± 1.74 | n.s. | 0.024 |
% of total FA | 3.44 ± 0.16 | 3.42 ± 0.15 | — | 3.44 ± 0.16 | — | n.s. |
C24:1n9 (μg mL−1) | 49.9 ± 1.45 | 47.7 ± 1.66 | n.s. | 49.9 ± 1.64 | n.s. | n.s. |
% of total FA | 5.03 ± 0.11 | 5.04 ± 0.11 | n.s. | 4.81 ± 0.12 | 0.031 | 0.001 |
∑TFA (μg mL−1) | 996 ± 20.6 | 947 ± 20.6 | 0.027 | 1043 ± 28.2 | n.s. | 0.003 |
∑SFA (μg mL−1) | 428 ± 9.33 | 408 ± 9.05 | 0.045 | 449 ± 12.3 | n.s. | 0.008 |
% of total FA | 42.9 ± 0.15 | 43.0 ± 0.14 | — | 43.1 ± 0.19 | — | n.s. |
∑MUFA (μg mL−1) | 202 ± 4.06 | 190 ± 4.23 | 0.009 | 206 ± 7.00 | n.s. | 0.013 |
% of total FA | 20.3 ± 0.25 | 20.1 ± 0.21 | 0.028 | 19.7 ± 0.26 | 0.012 | 0.003 |
∑PUFA (μg mL−1) | 367 ± 8.40 | 350 ± 7.94 | 0.039 | 387 ± 9.65 | n.s. | 0.002 |
% of total FA | 36.8 ± 0.23 | 36.9 ± 0.16 | n.s. | 37.2 ± 0.19 | 0.015 | 0.021 |
∑EPA + DHA (μg mL−1) | 40.2 ± 2.27 | 37.6 ± 1.95 | — | 40.8 ± 1.91 | — | n.s. |
% of total FA | 4.03 ± 0.18 | 3.97 ± 0.17 | n.s. | 3.93 ± 0.17 | 0.031 | 0.005 |
The two different dietary ratios of LA to ALA led to significantly different changes of the PUFA concentrations of ALA, LA, EPA and ∑EPA + DHA (Table S1†). In the following, the fatty acid concentrations are discussed unless the relative fatty acid distribution showed a different trend.
DPAn6 concentrations remained unchanged during loLA/hiALA and hiLA/loALA diet (Tables 4, 5 & S1†). Again, significantly (p = 0.026) different baseline DPAn6 concentrations were observed between loLA/hiALA and hiLA/loALA diet (Table S1†).
Numerous human studies have attempted to establish a defined dietary ratio of the precursor fatty acids LA and ALA to investigate the effect on the n3 PUFA status.20,27–44
According to a current review from Wood et al.,26 the majority of these studies, exhibited some or several methodological weaknesses such as studying males and females together,28–36 inappropriate or missing run-in and wash-out periods,28,39,43 inconsistent composition of the background diet, e.g. changes of EPA and DHA intake during interventions,31,37 inaccurate dietary records.29,31,33–35,37 These methodological weaknesses question the control and documentation of the PUFA intake and limit the ability to draw robust conclusions.26 Besides controlled PUFA intake and study conditions, several other factors have been proposed to influence ALA conversion in humans including age,21,22 BMI,22 smoking status,45 sex46–49 and genotype.13,50 For example, males and females are known to have different capacities for ALA conversion.13 Therefore, it is suggested that males and females are either stratified or studied separately.26
The aim of our study was to compare the effects of two different dietary LA/ALA ratios on fatty acid concentrations in RBC with special emphasis on LC n3 PUFAs. A homogenous study collective of healthy, non-smoking men within a narrow range regarding age (mean age 26.1 ± 4.53 years) and BMI (24.0 ± 1.65 kg m−2) was chosen to prevent/minimize the influence of gender, smoking, age, and BMI on PUFA metabolism. Likewise, our study approach includes further methodological considerations with the aim to overcome methodological weaknesses listed above. This involves in particular constant background diet and defined low-variable PUFA intake as well as subjects acting as their own controls (cross-over design), and run-in and wash-out phase. Other studies with the aim to modify LA and ALA intake mostly supplemented margarine and/or plant oils additionally to the normal background nutrition of the participants to achieve the desired ratio of LA to ALA.20,28,29,32,33,38–41,43 Studies, where subjects acted as their own controls are rare.20,39
With the two experimental diets a low-LA (2.78 en%) and a high-ALA (4.98 en%) diet and a high-LA (6.95 en%) and low-ALA (0.27 en%) diet were achieved, which correspond to a LA/ALA ratio of 0.56 ± 0.27:1 and 25.6 ± 2.41:1, respectively. These ratios can be classified as extreme examples of a desirable presumably health-promotive LA/ALA ratio (loLA/hiALA diet, <5:1) and an unfavorable LA/ALA ratio (hiLA/loALA diet, ≫5:1) as it is typical for Western diets. The variations in LA and ALA intake between the probands were minimal in both intervention periods. Moreover, no differences in the (extremely low) background intake of the LC PUFAs AA, EPA, DPAn3 and DHA were observed between the two intervention periods. Total PUFA intake was significantly higher in the loLA/hiALA diet compared to the hiLA/loALA diet due to the higher PUFA content of linseed oil (69.8% of total fatty acids) compared to sunflower oil (62.5% of total fatty acids). The higher MUFA intake in the hiLA/loALA diet was possibly the result of a higher MUFA content of sunflower oil (28.2% of total fatty acids) as compared to linseed oil (19.3% of total fatty acids). The intake of main nutrients (protein, carbohydrates, fat) and energy remained constant between the two intervention periods. These results suggest the applicability of our experimental design and the good compliance of the probands.
The loLA/hiALA diet was effective in increasing ALA and EPA concentrations in RBC membranes. This is in line with the observations of the systematic review of Wood et al.26 who state that a combination of a decrease of LA and a simultaneous increase of ALA intake is most effective in improving the n3 PUFA status.
As expected, the loLA/hiALA diet resulted in a strong increase of ALA concentrations of 332 ± 40% (day 7) and 354 ± 47% (day 14) in RBCs. This comparably large increase of ALA concentrations is greater compared to our previous study, where only ALA was given (12.9 g d−1) via the same linseed oil but without LA restriction.51 In this study the ALA increase in RBCs was 238 ± 24% after 7 days and 294 ± 23% after 3 weeks.51 The study collective was almost identical in both studies. Obviously, in this study the low LA content of the diet (all other dietary factors remained constant) contributed to the greater increase of ALA and n3 PUFAs. The reason is probably a competition between LA and ALA for the incorporation into cell membranes.14
Our finding that EPA concentrations in RBCs significantly increased by 35.0 ± 13% after 7 days and by 57.6 ± 18% after 14 days following the loLA/hiALA diet is a likely result of an increasing conversion of ALA to EPA, since no EPA was ingested via the background diet. Also other studies that increased the total ALA intake to 1.1–6.3 en% observed significantly higher EPA amounts, albeit with great variability27–29,36,38,40–44 reviewed by Wood et al.26 The efficiency of ALA conversion is, besides other factors, mainly dependent on the ALA dose, which essentially explains the fluctuations of the studies cited above.26 In a similar study, a 6-week intervention with ALA from linseed oil (LA/ALA ratio of 1:1) resulted in a 47.2% increase of relative EPA amounts in RBCs.33 The reason for this comparatively small increase after 6 weeks of intervention may be the lower ALA dose of 8.7 ± 2.2 g d−1.
Furthermore, it is discussed whether the ALA conversion also depends on the LA intake.12,13 Our data support this assumption as the ALA conversion to EPA can be further enhanced by reducing the LA content compared to our previous study with a higher LA intake.51 In our previous study with a similar ALA dose, but uncontrolled and highly variable LA intake (the LA intake was 9.32 ± 5.93 g d−1; 3.2 en%), a smaller increase of EPA concentrations in RBCs was observed (28.5 ± 10% after one week and 49.2 ± 14% after three weeks).51 However, due to the daily contact with the subjects in this study compared to the previous study, a higher level of compliance can be assumed. An influence of the EPA status can be excluded as the relative EPA amount in RBCs was almost the same in the study collective of both studies (0.53 ± 0.04% vs. 0.60 ± 0.04% of total fatty acids of RBC in the previous study). If larger studies confirm this phenomenon, the meaningfulness of recommending a LA/ALA ratio of 1:1 (ref. 19 and 52) without considering absolute LA and ALA intake amounts is questionable. At least the effect of the loLA/hiALA diet on the relative amount of ∑EPA + DHA in RBCs – which is an established marker for protective effects of n3 PUFA with regard to cardiac, cerebral and general health – is stronger compared to a simple ALA supplementation. The relative amount of ∑EPA + DHA in RBCs significantly (p = 0.019) increased by 11.3 ± 3.7% (4.03 ± 0.17% to 4.76 ± 0.20% of total fatty acids) in only 14 days after the loLA/hiALA diet, whereas it remained constant over 12 weeks of daily ALA supplementation without LA restriction.51
During the hiLA/loALA diet EPA concentrations slightly decreased by −11.2 ± 2% after 7 days and −12.9 ± 3.6% after 14 days. A study with a similar LA/ALA ratio of 26:1 including 7.8 g d−1 LA (1.4 en%) and 0.30 g d−1 ALA (0.09 en%) also observed decreasing EPA levels in cholesterol ester fatty acids.43 The reason for this EPA decrease may be the fish restricted diet which is lacking EPA and DHA43 and the small amount of ALA available for conversion to EPA. It is likely that the high amount of LA may competitively displace ALA for conversion enzymes.
Regarding the effects of ALA supplementation and different LA/ALA ratios on DHA, the results of current studies are heterogeneous. In some studies, DHA in blood remained constant,40 while others found increasing13,53–57 or decreasing51 levels. In the present study, we observed constant DHA concentrations in both intervention phases. Since DHA intake via the background diet was practically unchanged at a very low rate (30 mg vs. 20 mg per day), it is likely that increasing ALA and EPA levels after the loLA/hiALA diet are not converted to DHA. However, the timeframe of 14 days may be too short to observe significant changes in DHA concentrations. Wood et al.26 concluded that ALA supplementation studies with decreased LA intake – as our study – were able to increase DHA concentrations. Our results cannot confirm this observation, on the one hand possibly due to the short intervention time and on the other hand also due to the high ALA dose in this study. The high ALA intake may lead to a competitive saturation of the delta-6 desaturase, and thus the conversion of EPA to DHA (precisely of 24:5n3 to 24:6n3) may be inhibited by the conversion of ALA to EPA (precisely of 18:3n3 to 18:4n3).11 The shift in the ALA/EPA ratio in RBCs from 0.28 ± 0.03 (baseline) to 0.87 ± 0.10 (day 7) and 0.83 ± 0.10 (day 14) indicates that there is indeed a change in the substrate availability for the delta-6 desaturase. Hence, no clear conclusions can be drawn on whether it is possible to improve DHA status without eating fish or other marine products. However, the relative amount of ∑EPA + DHA in RBCs – which is an established marker for health protective effects of n3 PUFA – increased significantly (p = 0.019) in response to the loLA/hiALA from 4.03 ± 0.17% (day 0) to 4.76 ± 0.20% of total fatty acids (day 14). Although the increase is relatively small (and mainly due to the increase in EPA), it would be interesting to investigate the (health) effects on this parameter in an intervention period of more than two weeks.
Only minor changes of the RBC fatty acid patterns were observed in consequence of the hiLA/loALA diet. Concentrations of LA, ALA, AA and DHA were unchanged. Considering that the investigated LA/ALA ratio of 25.6:1 is close to that of the Western diet of 10–20:1,18,19 the almost constant fatty acid pattern is plausible and therefore in line with the expectations.
AA | Arachidonic acid |
ALA | Alpha linolenic acid |
BMI | Body mass index |
DHA | Docosahexaenoic acid |
DPAn3 | n3 docosapentaenoic acid |
DPAn6 | n6 docosapentaenoic acid |
en% | Percent of total energy |
EPA | Eicosapentaenoic acid |
FAME | Fatty acid methyl ester |
HDL | High density lipoprotein |
IS | Internal standard |
LA | Linoleic acid |
LC | Long chain |
LDL | Low density lipoprotein |
LLOQ | Lower limit of quantification |
MUFA(s) | Monounsaturated fatty acid(s) |
n.s. | Not significant |
n3 | Omega-3 |
n6 | Omega-6 |
PUFA(s) | Polyunsaturated fatty acid(s) |
RBCs | Red blood cells |
SD | Standard deviation |
SE | Standard error |
SFA(s) | Saturated fatty acid(s) |
TC | Total cholesterol |
TG | Triglycerides |
Footnote |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8fo00735g |
This journal is © The Royal Society of Chemistry 2018 |